Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [31] Expression of EGFR and HER2 in pediatric enbryonal brain tumours
    Stefanaki, K.
    Patereli, A.
    Anagnostopoulou, Doussis, I
    Moschovi, M.
    Constantinidou, Van Vliet C.
    Karamolegou, K.
    Sfakianos, G.
    Prodromou, F.
    Karentzou, O.
    VIRCHOWS ARCHIV, 2009, 455 : 154 - 155
  • [32] EGFR and HER2 expression in advanced biliary tract cancer
    Harder, Jan
    Waiz, Oliver
    Otto, Florian
    Geissler, Michael
    Olschewski, Manfred
    Weinhold, Brigitte
    Blum, Hubert E.
    Schmitt-Graeff, Annette
    Opitz, Oliver G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (36) : 4511 - 4517
  • [33] Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
    Foster, Scott A.
    Whalen, Daniel M.
    Oezen, Aysxeguel
    Wongchenko, Matthew J.
    Yin, JianPing
    Yen, Ivana
    Schaefer, Gabriele
    Mayfield, John D.
    Chmielecki, Juliann
    Stephens, Philip J.
    Albacker, Lee A.
    Yan, Yibing
    Song, Kyung
    Hatzivassiliou, Georgia
    Eigenbrot, Charles
    Yu, Christine
    Shaw, Andrey S.
    Manning, Gerard
    Skelton, Nicholas J.
    Hymowitz, Sarah G.
    Malek, Shiva
    CANCER CELL, 2016, 29 (04) : 477 - 493
  • [34] EGFR, HER2 and VEGF PathwaysValidated Targets for Cancer Treatment
    Michael F. Press
    Heinz-Josef Lenz
    Drugs, 2007, 67 : 2045 - 2075
  • [35] Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
    Estrada-Bernal, A.
    Le, A. T.
    Doak, A. E.
    Doebele, R. C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E45 - E45
  • [36] Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations
    De Greve, J.
    Teugels, E.
    Geers, C.
    De Mey, J.
    in'tveld, P.
    Decoster, L.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Schallier, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 556
  • [37] Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
    Li, Chenguang
    Sun, Yihua
    Fang, Rong
    Han, Xiangkun
    Luo, Xiaoyang
    Wang, Rui
    Pan, Yunjian
    Hu, Haichuan
    Zhang, Yang
    Pao, William
    Shen, Lei
    Ji, Hongbin
    Chen, Haiquan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) : 85 - 89
  • [38] HER4 Expression Was Related to the Sensitivity of EGFR-TKI in Non-Small Cell Lung Cancer
    Inoue, Masaaki
    Yoshida, Junichi
    Iwanami, Takashi
    Nabe, Yusuke
    Kanayama, Masatoshi
    Yasuda, Daisei
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S495 - S496
  • [39] Analysis of the EGFR mutations in non-small cell lung cancer patients after EGFR-TKI treatment.
    Yamaguchi, H.
    Ikeda, T.
    Tomonaga, N.
    Nakano, H.
    Kitazaki, T.
    Doi, S.
    Nakatomi, K.
    Iida, T.
    Nakamura, Y.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs)
    Marinovic, Sonja
    Berkovic, Maja Cigrovski
    Zjacic-Rotkvic, Vanja
    Kapitanovic, Sanja
    CANCER GENETICS, 2022, 266 : 44 - 50